Taysha Gene Therapies, Inc.
- TSHA
- NASDAQ
- Biotechnology
- Gene Therapy (AAV)
- CNS Disease Treatments
$3.62
Today −2.95%Quote Oct 16, 2026, 08:00 PM UTC
−29.84%over the last month
Max drawdown −32.0%From 1-month high −29.8%3 months −35.1%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Market value
$1.18B
Quote Oct 16
Next earnings
Nov 3
Expected, not confirmed
Analyst target
$14.00
+286.7% from here
Floor
—
Data unavailable
Where the price sits
18 analysts
Analyst range, low to high
$13.00$15.00
- Price $3.62
- Resistance $3.91
- Consensus $14.00
Analysts' average target sits about 287% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about TSHAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days freeWhere the money comes from
No revenue split by segment on file.
Industry
Biotechnology
Employees
99
Founded
2019